Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NovoMedix","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by NovoMedix

    Menu

    NovoMedix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NovoMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC

              Details:

              The SBIR grant will support the development of NMX1 and novel small molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.

              Lead Product(s): NMX1

              Therapeutic Area: Oncology Product Name: NMX1

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Heart, Lung, and Blood Institute

              Deal Size: $2.0 million Upfront Cash: Undisclosed

              Deal Type: Funding May 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY